1224 related articles for article (PubMed ID: 18945412)
21. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
22. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.
Castellsagué X; Díaz M; de Sanjosé S; Muñoz N; Herrero R; Franceschi S; Peeling RW; Ashley R; Smith JS; Snijders PJ; Meijer CJ; Bosch FX;
J Natl Cancer Inst; 2006 Mar; 98(5):303-15. PubMed ID: 16507827
[TBL] [Abstract][Full Text] [Related]
23. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination.
Franco EL; Cuzick J; Hildesheim A; de Sanjosé S
Vaccine; 2006 Aug; 24 Suppl 3():S3/171-7. PubMed ID: 16844268
[TBL] [Abstract][Full Text] [Related]
24. The impact of cytology screening and HPV vaccination on the burden of cervical cancer.
Tay K; Tay SK
Asia Pac J Clin Oncol; 2011 Jun; 7(2):154-9. PubMed ID: 21585695
[TBL] [Abstract][Full Text] [Related]
25. Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain.
Gauthier A; Martín-Escudero V; Moore L; Ferko N; de Sanjosé S; Pérez-Escolano I; Catalá-López F; Ferrer E; Bosch FX
Eur J Public Health; 2008 Dec; 18(6):674-80. PubMed ID: 18641420
[TBL] [Abstract][Full Text] [Related]
26. Reducing patient risk for human papillomavirus infection and cervical cancer.
Herbert J; Coffin J
J Am Osteopath Assoc; 2008 Feb; 108(2):65-70. PubMed ID: 18303060
[TBL] [Abstract][Full Text] [Related]
27. HPV vaccines: state of the art.
D'Andrilli G; Bovicelli A; Giordano A
J Cell Physiol; 2010 Sep; 224(3):601-4. PubMed ID: 20432468
[TBL] [Abstract][Full Text] [Related]
28. [Vaccination perspective against human papillomavirus and consequences for the screening of uterine cervical neoplasm].
Delvenne P
Bull Mem Acad R Med Belg; 2007; 162(10-12):483-8; discussion 489-90. PubMed ID: 18557390
[TBL] [Abstract][Full Text] [Related]
29. Prevention of cervical cancer: where immunology meets diagnostics.
Meijer CJ; Heideman DA; Berkhof H; Snijders PJ
Immunol Lett; 2009 Feb; 122(2):126-7. PubMed ID: 19100775
[TBL] [Abstract][Full Text] [Related]
30. [Implementation of HPV vaccination in Germany].
Schreckenberger C; Kaufmann AM; Schneider A
Dtsch Med Wochenschr; 2007 Oct; 132(42):2221-4. PubMed ID: 17926251
[No Abstract] [Full Text] [Related]
31. Prevalence and genotype distribution of multiple human papillomavirus infection in the uterine cervix: a 7.5-year longitudinal study in a routine cytology-based screening population in West Germany.
Kovács K; Varnai AD; Bollmann M; Bankfalvi A; Szendy M; Speich N; Schmitt C; Pajor L; Bollmann R
J Med Virol; 2008 Oct; 80(10):1814-23. PubMed ID: 18712836
[TBL] [Abstract][Full Text] [Related]
32. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
33. Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study.
Dondog B; Clifford GM; Vaccarella S; Waterboer T; Unurjargal D; Avirmed D; Enkhtuya S; Kommoss F; Wentzensen N; Snijders PJ; Meijer CJ; Franceschi S; Pawlita M
Cancer Epidemiol Biomarkers Prev; 2008 Jul; 17(7):1731-8. PubMed ID: 18628425
[TBL] [Abstract][Full Text] [Related]
34. How much cervical cancer in Australia is vaccine preventable? A meta-analysis.
Brotherton JM
Vaccine; 2008 Jan; 26(2):250-6. PubMed ID: 18068276
[TBL] [Abstract][Full Text] [Related]
35. Vaccination against human papillomavirus.
BMJ Group
Drug Ther Bull; 2008 Dec; 46(12):89-93. PubMed ID: 19056700
[TBL] [Abstract][Full Text] [Related]
36. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives.
Insinga RP; Dasbach EJ; Elbasha EH; Liaw KL; Barr E
Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):709-15. PubMed ID: 17416761
[TBL] [Abstract][Full Text] [Related]
37. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium.
Arbyn M; Benoy I; Simoens C; Bogers J; Beutels P; Depuydt C
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):321-30. PubMed ID: 19124515
[TBL] [Abstract][Full Text] [Related]
38. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change.
Franco EL; Mahmud SM; Tota J; Ferenczy A; Coutlée F
Arch Med Res; 2009 Aug; 40(6):478-85. PubMed ID: 19853188
[TBL] [Abstract][Full Text] [Related]
39. Role of human papilloma virus testing in cervical cancer prevention.
Fey MC; Beal MW
J Midwifery Womens Health; 2004; 49(1):4-13. PubMed ID: 14710135
[TBL] [Abstract][Full Text] [Related]
40. Quadrivalent human papillomavirus vaccine.
Barr E; Tamms G
Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
